| Victor Henry Gajewski, OTR/L CHT | |
|
3726 Broadway,, Suite 201, Everett, WA 98201 | |
| (425) 317-9119 | |
| (425) 317-9118 |
| Full Name | Victor Henry Gajewski |
|---|---|
| Gender | Male |
| Speciality | Occupational Therapy |
| Experience | 31 Years |
| Location | 3726 Broadway,, Everett, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164451225 | NPI | - | NPPES |
| 8348286 | Medicaid | WA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | OT00004040 (* (Not Available)) | Secondary |
| 225XH1200X | Occupational Therapist - Hand | OT00004040 (Washington) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Western Washington Medical Group Inc Ps | 7517870314 | 101 |
News Archive
Life Technologies Corporation has signed an exclusive license agreement for novel technology that enables synthetic biologists to effectively program and control the genetic circuitry in engineered pathways and organisms.
Chairman Edolphus (Ed) Towns (D-10th-New York), a long-time AbilityOne Champion, has earned the "Spirit of Independence Award," in recognition of his lifetime commitment to advance economic and personal independence for people who are blind. National Industries for the Blind's President and CEO Kevin Lynch presented the prestigious award to Chairman Towns at a ceremony on Capitol Hill on July 30, 2010.
ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), today provided an update on its European commercial launch of MuGard, an FDA approved treatment for oral mucositis, a debilitating side effect of radiation treatment and chemotherapy.
The world's leading mass spectrometer manufacturers have agreed to license technology that enabled University of Southern California (USC) researchers to develop software that, for the first time, allows scientists to easily use and share research data collected across proprietary platforms.
Researchers from the John Theurer Cancer Center at Hackensack University Medical Center played an important role in a study that led to the Food & Drug Administration's (FDA) recent fast tracking of ipilimumab, a promising treatment for metastatic melanoma. The FDA based its decision largely on the results of a pivotal study published in the New England Journal of Medicine on August 19, 2010 – the same day the agency accepted Bristol-Myers Squibb's application for the drug's approval and granted the application priority review status.
› Verified 6 days ago
| Provider Name | Western Washington Medical Group Inc Ps |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1396413803 PECOS PAC ID: 7517870314 Enrollment ID: O20031107000469 |
News Archive
Life Technologies Corporation has signed an exclusive license agreement for novel technology that enables synthetic biologists to effectively program and control the genetic circuitry in engineered pathways and organisms.
Chairman Edolphus (Ed) Towns (D-10th-New York), a long-time AbilityOne Champion, has earned the "Spirit of Independence Award," in recognition of his lifetime commitment to advance economic and personal independence for people who are blind. National Industries for the Blind's President and CEO Kevin Lynch presented the prestigious award to Chairman Towns at a ceremony on Capitol Hill on July 30, 2010.
ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), today provided an update on its European commercial launch of MuGard, an FDA approved treatment for oral mucositis, a debilitating side effect of radiation treatment and chemotherapy.
The world's leading mass spectrometer manufacturers have agreed to license technology that enabled University of Southern California (USC) researchers to develop software that, for the first time, allows scientists to easily use and share research data collected across proprietary platforms.
Researchers from the John Theurer Cancer Center at Hackensack University Medical Center played an important role in a study that led to the Food & Drug Administration's (FDA) recent fast tracking of ipilimumab, a promising treatment for metastatic melanoma. The FDA based its decision largely on the results of a pivotal study published in the New England Journal of Medicine on August 19, 2010 – the same day the agency accepted Bristol-Myers Squibb's application for the drug's approval and granted the application priority review status.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Victor Henry Gajewski, OTR/L CHT 3726 Broadway,, Suite 201, Everett, WA 98201 Ph: (425) 317-9119 | Victor Henry Gajewski, OTR/L CHT 3726 Broadway,, Suite 201, Everett, WA 98201 Ph: (425) 317-9119 |
News Archive
Life Technologies Corporation has signed an exclusive license agreement for novel technology that enables synthetic biologists to effectively program and control the genetic circuitry in engineered pathways and organisms.
Chairman Edolphus (Ed) Towns (D-10th-New York), a long-time AbilityOne Champion, has earned the "Spirit of Independence Award," in recognition of his lifetime commitment to advance economic and personal independence for people who are blind. National Industries for the Blind's President and CEO Kevin Lynch presented the prestigious award to Chairman Towns at a ceremony on Capitol Hill on July 30, 2010.
ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), today provided an update on its European commercial launch of MuGard, an FDA approved treatment for oral mucositis, a debilitating side effect of radiation treatment and chemotherapy.
The world's leading mass spectrometer manufacturers have agreed to license technology that enabled University of Southern California (USC) researchers to develop software that, for the first time, allows scientists to easily use and share research data collected across proprietary platforms.
Researchers from the John Theurer Cancer Center at Hackensack University Medical Center played an important role in a study that led to the Food & Drug Administration's (FDA) recent fast tracking of ipilimumab, a promising treatment for metastatic melanoma. The FDA based its decision largely on the results of a pivotal study published in the New England Journal of Medicine on August 19, 2010 – the same day the agency accepted Bristol-Myers Squibb's application for the drug's approval and granted the application priority review status.
› Verified 6 days ago
Mrs. Jennifer Marie Coleman, OTR/L Occupational Therapist Medicare: Medicare Enrolled Practice Location: 1919 112th St Sw, Everett, WA 98204 Phone: 425-513-1600 Fax: 425-513-1800 | |
Karlyn Dixon, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1919 112th St Sw, Everett, WA 98204 Phone: 425-513-1600 | |
Michelle Hopstad, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1321 Colby Ave, Everett, WA 98201 Phone: 425-261-3825 | |
Patsy L Whitright, OT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 5029 Evergreen Way, Everett, WA 98203 Phone: 425-252-1642 Fax: 425-258-1824 | |
Mr. Colleen Thomas, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 916 Pacific Ave, Everett, WA 98201 Phone: 425-258-7123 | |
Mrs. Jane Marisse Warner, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 916 Pacific Ave, Everett, WA 98207 Phone: 425-258-7571 | |
Sharon L Moore, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 9600 Holly Dr, Everett, WA 98204 Phone: 425-366-2500 |